缺血性心肌病患者的室性心动过速消融:谁、何时与如何?
本文综述了缺血性心肌病合并室性心动过速(VT)患者导管消融的随机试验与当代技术。VT最常见机制为瘢痕内折返,ICD可降低猝死风险但不预防VT,抗心律失常药物复发率高且副作用不可忽视。患者选择对优化临床结局至关重要,综述旨在明确哪些患者应接受VT消融、理想干预时机及如何实现无复发。
要点
- 缺血性心肌病VT最常见机制为瘢痕内折返,可表现为规律持续性宽QRS心动过速。
- ICD降低猝死风险但不预防VT,抗心律失常药物复发率高且副作用不可忽视。
- 患者选择对VT消融获得最佳临床结局至关重要。
核心结论
- 导管消融技术进展使VT消融结局改善,但需重视患者选择以达最佳临床结局。
研究设计与样本
- 综述,汇总导管消融治疗VT的随机试验及当代VT消融技术。
主要发现
- 缺血性心肌病VT最常见机制为经病变心肌窄通道的折返。
- ICD可降低猝死风险但不预防VT,仅在发生时治疗。
- 抗心律失常药物抑制VT复发率高且不良反应不可忽视。
- 近几十年导管消融在标测精度与消融效力方面显著进步,近期研究显示结局改善。
临床怎么用
- 对缺血性心肌病合并VT患者,应综合评估以选择适合导管消融者。
- 需权衡ICD、抗心律失常药物与导管消融在VT管理中的作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Ventricular tachycardia (VT) is an abnormal rapid heart rhythm that most commonly occurs in the setting of ventricular scar. In patients with ischaemic cardiomyopathy and VT, the most common mechanism is re-entry of electrical activation through narrow channels of diseased myocardium manifesting on the ECG as a regular sustained wide-complex tachycardia that can present clinically with sudden cardiac death (SCD).Implantable cardioverter-defibrillators (ICDs) are proven to reduce the risk of SCD, but do not prevent VT; they treat it when it occurs. Although antiarrhythmic drug therapy has a long history of use to suppress VT, recurrence rates remain high and adverse effects are not negligible. Significant advances have been made over the past decades in catheter-based techniques for VT suppression. Improvements in both mapping accuracy and ablation efficacy have resulted in recent studies demonstrating improved outcomes of catheter ablation of VT. Patient selection for a procedural approach will be important for achieving optimal clinical outcomes.This review provides a comprehensive overview of randomised trials of catheter ablation for VT as well as contemporary VT ablation techniques, and aims to understand which patients should undergo VT ablation, when is the ideal timing for intervention, and how best to achieve freedom from recurrent VT.
引用
- Hadjis A, De Marco C, Raymond JM, et al. Ventricular tachycardia ablation in ischaemic cardiomyopathy: who, when and how? Heart. 2026. PMID: 41057248. doi:10.1136/heartjnl-2024-325370
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。